RxDoctor Payments DataLook up a doctor →

Campbell Sindel, MD

Pulmonary Disease · Mobile, ALNPI 1578975181

Payments from drug & device makers

$14,092in general payments, 2019–2025

Across 432 payments — averaging $32.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$6K
  • GSK$2K
  • AstraZeneca$2K
  • Boehringer Ingelheim$890
  • Takeda Pharmaceuticals U.S.A., Inc.$540
  • Genentech USA, Inc.$435
  • plus $3K from 35 others

What the payments were for

  • Travel & lodging$8376%
  • Food & beverage$8,75562%
  • Education$4,50032%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,092 in reported general payments places this provider in the 75th percentile of 215 pulmonary disease providers in Alabama.

See all pulmonary disease providers in Alabama

Medicare billing

Part B allowed, 2024
$191,289
Medicare patients
415
Services billed
3,221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter873$621,716
OfevNintedanib Esylate15$192,753
Breztri AerosphereBudesonide/Glycopyr/Formoterol193$152,484
Spiriva RespimatTiotropium Bromide72$39,921
Breo ElliptaFluticasone/Vilanterol74$32,384
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr51$30,954
Albuterol Sulfate HfaAlbuterol Sulfate694$16,722
Stiolto RespimatTiotropium Br/Olodaterol Hcl21$14,282
SymbicortBudesonide/Formoterol Fumarate58$13,536
Fluticasone-SalmeterolFluticasone Propion/Salmeterol55$12,319
Varenicline Tartrate41$9,160
Wixela InhubFluticasone Propion/Salmeterol49$7,728
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$6,184
Incruse ElliptaUmeclidinium Bromide13$4,381
BreynaBudesonide/Formoterol Fumarate15$3,291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$1,800$689,4351,011 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$890$246,957108 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,525$166,020251 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 215 pulmonary disease providers in Alabama.

Other pulmonary disease in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →